SLC5A2 and chronic kidney disease: This difference may stem from differences in patient characteristics (e.g., inclusion of CKD patients in our study versus exclusion of eGFR < 45 mL/min/1.73 m2 in Pathan et al.'s study), study design (e.g., initiation of SGLT2 inhibitors during Ramadan in your study versus stable use in Pathan et al.'s study), and environmental factors (e.g., fasting duration and hydration status).